-- 奥本海默公司周二发布的一份报告指出，随着Climb Bio (CLYM) 免疫学产品线（尤其是其用于治疗IgA肾病的在研疗法）的预期更新，分析师对其前景更加乐观。 奥本海默强调，对Climb Bio的抗APRIL项目（包括CLYM116）的信心日益增强，并指出其潜在的同类最佳疗效、超出预期的蛋白尿减少效果、更长的给药间隔以及良好的安全性是关键的差异化优势。 报告称，即将公布的皮下注射布多普鲁（budoprutug）和CLYM116的临床试验数据可能成为关键催化剂，有望验证Climb Bio的IgA肾病治疗策略。如果结果积极，强劲的定价策略将支撑其商业增长。 奥本海默维持对该股的“跑赢大盘”评级，并将目标价从10美元上调至18美元。 Climb Bio股价周二上涨超过6%。
Price: $9.49, Change: $+0.52, Percent Change: +5.80%
Shanxi Lu'an Environmental Energy Development (SHA:601699) posted 2025 attributable net profit of 1.12 billion yuan, down 54% from 2.45 billion yuan the previous year.Earnings per share declined to 0.37 yuan from 0.82 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue fell 22% year over year to 27.8 billion yuan from 35.9 billion yuan.Shares of the coal miner rose 3% in recent trade.
WA1 Resources (ASX:WA1) reported a cash balance of about AU$131 million as at March 31, according to a Monday Australian bourse filing.The company said it has now received all data inputs for a mineral resource estimate update expected in the June quarter.The company completed essential data capture activities in 2025, which is now facilitating project development studies, permitting and approvals workstreams, the filing added.The company's shares rose 7% in recent Monday trade.
Bank of Ningbo (SHE:002142) posted first-quarter attributable net profit of 8.18 billion yuan, up 10% from 7.42 million yuan the previous year.Earnings per share rose to 1.24 yuan from 1.12 yuan, according to a weekend filing with the Shenzhen bourse.Operating income rose 10% year over year to 20.4 billion yuan from 18.5 billion yuan.Shares of the bank rose 3% in recent trade.